STOCKHOLM, Jan. 4, 2024
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a
pharmaceutical company focused on developing innovative treatments
for cancer in areas of high unmet medical need, announced today
that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango),
has dosed the first patient with TNG348, a novel USP1
inhibitor. Tango received U.S. Food and Drug Administration
clearance on its Investigational New Drug application for TNG348 in
September 2023.
TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor
for the treatment of BRCA1/2-mutant and other homologous
recombination deficiency (HRD)+ cancers. HRD+ cancers, including
BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of
breast cancers, 10% of prostate cancers and 5% of pancreatic
cancers. Tango is developing TNG348 from the preclinical USP1
program licensed from Medivir in 2020.
In the study, TNG348 will be evaluated both as single agent and
in combination with olaparib (PARP-inhibitor) in patients with
BRCA1/2-mutant and other HRD+ cancers. Preclinical data has shown
synergistic effect with PARP inhibitors in PARP naïve models,
including models with resistance to PARP inhibitors.
- "The preclinical data generated
by Tango for TNG348 is promising and dosing the first patient in a
clinical study is encouraging for patients with HRD+ cancers. The
efforts undertaken by Tango to develop TNG348 into a
clinical-staged drug are impressive and we will continue to follow
the clinical development of TNG348 with great anticipation," says
Jens Lindberg, CEO of Medivir.
Under the licensing agreement, Medivir is entitled to multiple
development and commercial milestone payments as well as royalties
on future sales. Dosing the first patient in a clinical trial
triggers a milestone payment.
For additional information, please
contact;
Magnus Christensen,
CFO, Medivir AB
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (fostrox), a pro-drug designed to
selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Medivir's share (ticker: MVIR) is listed
on Nasdaq Stockholm's Small Cap list. www.medivir.com.
The following files are available for download:
|
https://mb.cision.com/Main/652/3904079/2522650.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivirs-licensee-tango-therapeutics-has-dosed-the-first-patient-with-tng348-a-novel-usp1-inhibitor-in-a-phase-12-clinical-study-302026095.html
SOURCE Medivir